Skip to main content
SpringerLink
Log in

Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The diagnosis of malignant diseases worldwide has been determined using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Glucose transporter type 1 (Glut-1) is a key protein associated with the accumulation of FDG in cancer cells. This study evaluated the relationship between Glut-1 expression and FDG accumulation to determine the usefulness of FDG-PET for prediction of long-term outcomes of pancreatic cancer.

Methods

The expression of Glut-1 was immunohistochemically examined in 138 surgically resected pancreatic cancer specimens. The Glut-1-positive and Glut-1-negative groups were analyzed with respect to their clinicopathologic characteristics and prognosis. Before surgery, 93 patients underwent FDG-PET and measurement of the corrected maximum standardized uptake value (cSUVmax). The relationship between Glut-1 expression and cSUVmax were examined, and prognostic factors were identified using uni- and multivariate analyses.

Results

Glut-1 was positive in 69 patients (50%). The median relapse-free and overall survival times were significantly shorter in the Glut-1-positive group (11 vs. 22 months, respectively) than in the Glut-1-negative group (23 vs. 42 months, respectively). The cSUVmax was significantly associated with long-term survival. The relapse-free and overall survival rates were significantly poorer in the high-cSUVmax group than in the low-cSUVmax group. Glut-1 expression was associated with cSUVmax accumulation. In the multivariate Cox regression analysis using forward stepwise selection, male gender, positive lymph node metastases, high CA19-9, and high cSUVmax were identified as independent prognostic factors for pancreatic cancer.

Conclusion

A significant relationship exists between high preoperative cSUVmax and Glut-1 expression. High cSUVmax is one of the prognostic factors for overall survival after resection of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:2140–1.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  3. Madsen PH, Holdgaard PC, Christensen JB, et al. Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2084–97.

    Article  CAS  PubMed  Google Scholar 

  4. Park JT, Roh JL, Kim JS, et al. (18)F FDG PET/CT versus CT/MR imaging and the prognostic value of contralateral neck metastases in patients with head and neck squamous cell carcinoma. Radiology. 2016;279:481–91.

    Article  PubMed  Google Scholar 

  5. Vali R, Loidl W, Pirich C, et al. Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging. 2015;5:96–108.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Xiao Y, Wang L, Jiang X, et al. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. Nucl Med Commun. 2016;37:1180–88.

    Article  PubMed  Google Scholar 

  7. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.

    CAS  PubMed  Google Scholar 

  8. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.

    Article  Google Scholar 

  9. Denko NC. Hypoxia, HIF1, and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13.

    Article  CAS  PubMed  Google Scholar 

  10. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654–62.

    Article  CAS  PubMed  Google Scholar 

  11. Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999;84:3228–34.

    CAS  PubMed  Google Scholar 

  12. Sakashita M, Aoyama N, Minami R, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001;37:204–9.

    Article  CAS  PubMed  Google Scholar 

  13. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928–34.

    CAS  PubMed  Google Scholar 

  14. Barbaro D, Di Bari L, Gandin V, et al. Glucose-coated superparamagnetic iron oxide nanoparticles prepared by metal vapour synthesis are electively internalized in a pancreatic adenocarcinoma cell line expressing GLUT1 transporter. PLoS ONE. 2015;10:e0123159.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pizzi S, Porzionato A, Pasquali C, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2009;24:175–85.

    PubMed  Google Scholar 

  16. Davis-Yadley AH, Abbott AM, Pimiento JM, et al. Increased expression of the glucose transporter type 1 gene is associated with worse overall survival in resected pancreatic adenocarcinoma. Pancreas. 2016;45:974–9.

    Article  CAS  PubMed  Google Scholar 

  17. Kitasato Y, Yasunaga M, Okuda K, et al. Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas. Pancreas. 2014;43:1060–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sawayama H, Ishimoto T, Watanabe M, et al. High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence. Ann Surg Oncol. 2014;21:1756–62.

    Article  PubMed  Google Scholar 

  19. Ma C, Komohara Y, Ohnishi K, et al. Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Science. 2016;107:700–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61:92–105.

    Article  PubMed  Google Scholar 

  21. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–80.

    CAS  PubMed  Google Scholar 

  22. Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957–63.

    Article  PubMed  Google Scholar 

  23. Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013;1835:164–9.

    CAS  PubMed  Google Scholar 

  24. Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136:548–56.

    Article  PubMed  Google Scholar 

  25. Kaira K, Serizawa M, Koh Y, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer. 2014;83:197–204.

    Article  PubMed  Google Scholar 

  26. Riedl CC, Akhurst T, Larson S, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nuclear Med. 2007;48:771–5.

    Article  Google Scholar 

  27. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16:39–44.

    Article  PubMed  Google Scholar 

  28. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727–35.

    CAS  PubMed  Google Scholar 

  29. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30:1359–67.

    CAS  PubMed  Google Scholar 

  30. Lyshchik A, Higashi T, Hara T, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007;25:154–62.

    Article  CAS  PubMed  Google Scholar 

  31. Basturk O, Singh R, Kaygusuz E, et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011;40:187–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Paquin SC, Gariepy G, Lepanto L, et al. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. Gastrointest Endosc. 2005;61:610–11.

    Article  PubMed  Google Scholar 

  33. Chong A, Venugopal K, Segarajasingam D, et al. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. Gastrointest Endosc. 2011;74:933–5.

    Article  PubMed  Google Scholar 

  34. Katanuma A, Maguchi H, Hashigo S, et al. Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. Endoscopy. 2012;44:E160–1.

    Article  PubMed  Google Scholar 

  35. Aloj L, Caraco C, Jagoda E, et al. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59:4709–14.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors are grateful for the excellent help provided by the technical assistants, Ms. Taniguchi and Ms. Yokoyama.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan

    Akira Chikamoto MD, FACS, Risa Inoue MD, Daisuke Hashimoto MD, PhD, FACS, Yo-ichi Yamashita MD, PhD, FACS, Naoya Yoshida MD, PhD, FACS & Hideo Baba MD, PhD, FACS

  2. Department of Cell Pathology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan

    Yoshiaki Komohara MD, PhD

  3. Department of Biostatistics, Yokohama City University, Yokohama, Japan

    Kentaro Sakamaki PhD & Takeharu Yamanaka PhD

  4. Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    Shinya Shiraishi MD, PhD & Yasuyuki Yamashita MD, PhD

  5. Department of Surgery, Saiseikai Kumamoto Hospital, Kumamoto, Japan

    Hiroshi Takamori MD, PhD, FACS

Authors
  1. Akira Chikamoto MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Risa Inoue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshiaki Komohara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kentaro Sakamaki PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Hashimoto MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Shiraishi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Takamori MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yo-ichi Yamashita MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoya Yoshida MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeharu Yamanaka PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasuyuki Yamashita MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hideo Baba MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba MD, PhD, FACS.

Ethics declarations

Disclosure

There are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chikamoto, A., Inoue, R., Komohara, Y. et al. Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer. Ann Surg Oncol 24, 2040–2046 (2017). https://doi.org/10.1245/s10434-017-5799-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-5799-1

Keywords

Search

Navigation